Our mission is to profoundly improve people’s lives by delivering a new class of RNA therapeutics – AOCs. Our proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Our advancing and expanding pipeline includes multiple skeletal muscle programs. We are also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution.
Below is a list of individual analysts that we are aware of that currently follow Avidity Biosciences.
|Cowen & Company||Ritu Baral|
|Credit Suisse||Judah Frommer|
|Evercore ISI||Josh Schimmer|
|SVB Leerink||Joseph P. Schwartz|
|Wells Fargo||Yanan Zhu|
Please note, that any opinions, estimates or forecasts regarding performance made by these analysts do not represent Avidity Biosciences or its management team. Avidity Biosciences is under no obligation to update this list, thus it may not be complete or up to date.